Parnax Lab Ltd Share Price Today - Parnax Lab Ltd Stock Price Live NSE/BSE

Parnax Lab Ltd

NSE: BSE: 506128

₹129.90

(-0.08%)

Mon, 16 Mar 2026, 10:39 pm

MTF 5xInvest in Parnax Lab Ltd with 5x Leverage Buy with MTF

Market Cap1.48B

PE Ratio11.90

Dividend0

Health Technology

Pharmaceuticals: Major

24.5K

Parnax Lab Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
142.54
Net Profit
11.54
P/B
1.48
Sector P/E
32.17
P/E
10.67
EV/EBITDA
6.67
Debt/Equity (Industry)
0.25
Interest Cover (Industry)
11.42
ROCE (Industry)
16.55
RONW (Industry)
14.50
ROE
14.92
ROCE
13.77
Debt/Equity
0.97
EPS (TTM)
11.72
Dividend Yield
0
Book Value
78.35
Interest Cover
3.91

Analysis

all

Pros

Parnax Lab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
Parnax Lab has been profitable on average in the past, therefore cash runway is not a concern.
Debt is well covered by operating cash flow (21.9%, greater than 20% of total debt).
Debt is covered by short term assets, assets are 1x debt.

Cons

Unable to evaluate Parnax Lab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Parnax Lab's dividend against the top 25% market benchmark as the company has not reported any payouts.
Parnax Lab is making a loss, therefore interest payments are not well covered by earnings.
Parnax Lab's level of debt (109.9%) compared to net worth is high (greater than 40%).
High level of physical assets or inventory.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	72.30	72.30	72.30	72.30	72.30
FII	0	0	0	0	0
DII	0	0	0	0	0
Public	27.70	27.70	27.70	27.70	27.70
Government	0	0	0	0	0

Technical Analysis

RSI

42.55

MACD

0.45

50 DMA

122.72

200 DMA

122.22

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	168.82	147.82	139.63	126.82	118.63	105.82	84.82
Fibonacci	147.82	139.79	134.84	126.82	118.79	113.84	105.82
Camarilla	137.22	135.30	133.38	126.82	129.52	127.60	125.67

Pivots Level: Classic

+42

168.82

+21

147.82

+12.82

139.63

126.82

Pivot Point

LTP: 120

-8.18

118.63

-21

105.82

-42

84.82

Moving Average

SMAEMA

Period

Value

10-EMA
126.04
20-EMA
126.15
30-EMA
125.56
50-EMA
124.82
100-EMA
124.13
200-EMA
122.81

Announcement Date	Purpose	Action
13 Feb 2026	board-meetings	Quarterly Results, Half Yearly Results
14 Nov 2025	board-meetings	Quarterly Results
13 Aug 2025	agm
17 Sept 2024	agm
11 Aug 2023	agm
11 Aug 2022	agm
01 Jan 2022	egm
14 Aug 2021	agm

Parnax Lab Ltd

Sun Pharmaceutical Industries Ltd

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd

Cipla Ltd

Parnax Lab Ltd About

Parnax Lab princi pally engaged in the business activities of manufacturingand export of Pharmaceutical Formulations.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1982

Headquarters

CEO

Employees

Contact

Website

http://www.naxparlab.com

compliance@naxparlab.com

Phone

91-022-6825 2525

Location

Gala 114 Bldg No 8, Jogani Ind Complex Chunabhatti, Mumbai, Maharashtra, 400022

Year	History
2009	The company appointed Mr. Rasik Chaturvedi and Mr. Dilip Pimparkar as Additional Directors Mr. Rasik Chaturvedi and Mr. Dilip Pimparkar were inducted on the Audit Committee of the company
2010	The company appointed Mr. Mahesh Naidu as Additional Independent Non Executive Director
2011	The registered office of the company was shifted from Gala 107, Bldg. No. 9, Jogani Industrial Complex, Chunabhatti, Mumbai - 400022 to Gala 114, Bldg. No. 8, Jogani Industrial Complex, Chunabhatti, Mumbai - 400022
2012	The company changed its name from Krishna Deep Trade & Investments Ltd. to Parnax Lab Ltd.

Client Name	Order Side	QTY	Avg Price	Date
NAVRATANMAL BADOLA (HUF)	Sell	53695	55.27	18 May 2018
DHEERAJ KUMAR LOHIA	Buy	53737	58.81	24 Apr 2018
BHAVIN Y MEHTA	Sell	47315	53.62	05 Jun 2017
BHAVIN Y MEHTA	Buy	47315	52.25	05 Jun 2017
SETU SECURITIES PVT LTD	Sell	78000	74.14	19 Apr 2017
SETU SECURITIES PVT LTD	Buy	2513	74.3	19 Apr 2017
SETU SECURITIES PVT LTD	Buy	88166	70.8	18 Apr 2017
NIKHIL VORA	Buy	50000	64.95	17 Apr 2017
SETU SECURITIES PVT LTD	Buy	48246	63.88	13 Apr 2017
PORINJUV VELIYATH	Buy	100000	55.52	30 Mar 2017

Parnax Lab Ltd News

Parnax Lab Q3FY26 Results: Revenue Jumps 175% YoY

Parnax Lab Limited reported strong Q3FY26 results with consolidated revenue rising 56.45% to ₹6,294.15 lakhs and net profit increasing 124.29% to ₹271.47 lakhs compared to previous year.

13 Feb 2026

co actions results

Parnax Lab Limited Reports Quarterly Financial Results for Period Ended September 30, 2025

Parnax Lab Limited's Board of Directors approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, during their meeting held on November 14, 2025. The pharmaceutical formulations company's results show consolidated revenue from operations and include subsidiary Naxpar Pharma Private Limited's performance with total assets of Rs. 20,135.19 lakhs.

14 Nov 2025

earnings

Parnax Lab Limited Reports Q1 FY2026 Results, Schedules 43rd AGM and Appoints New Secretarial Auditor

Parnax Lab Limited approved its unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. On a standalone basis, the company reported revenue from operations of Rs. 196.75 lakhs and net profit of Rs. 23.49 lakhs with basic EPS of Rs. 0.20. On a consolidated basis, revenue from operations reached Rs. 5,337.55 lakhs with net profit of Rs. 327.49 lakhs and basic EPS of Rs. 2.85. The company scheduled its 43rd Annual General Meeting for September 29, 2025, to be conducted via video conferencing. Additionally, the board approved the appointment of M/s HSPN & Associates LLP as Secretarial Auditor for a five-year term from FY 2025-2026 to FY 2029-2030, subject to shareholder approval at the upcoming AGM.

13 Aug 2025

earnings

Parnax Lab: Q3 Profit Plunges 44.5% Amid Revenue Decline

Parnax Lab reported Q3 FY25 results with revenue down 21.12% YoY to ₹40.22 crore and profit falling 44.5% to ₹1.21 crore. Operating income decreased by 53.11% QoQ and 40.57% YoY. EPS dropped to ₹1.06, a 44.21% YoY decline.

12 Feb 2025

earnings

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800

Parnax Lab Ltd

Parnax Lab Share Price Live Chart

Summary

Analysis

Financials

Ratios

Shareholding

Technical Analysis

Corporate Actions

Peer Comparison

Parnax Lab Ltd About

Contact

Parnax Lab Ltd Company History

Deals

Parnax Lab Ltd News